Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01932125

NCT01932125
Completed Phase 4

Who may be able to join

Who might be able to join this trial:

  • You have been prescribed bevacizumab, or are already being treated with it, for advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (at a stage classified as IIIb, IIIc, or IV) as part of your normal medical care

Who may not be able to join:

  • You are not considered suitable to receive bevacizumab based on the official prescribing guidelines used in your country or region

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 4: approximately Approved of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 4
Sponsor
Hoffmann-La Roche
Registry
clinicaltrials_gov
Start date
5 December 2018
Est. completion
18 June 2025

Where this trial is recruiting

🇮🇳 India

Primary endpoints

Safety: Incidence of adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov